BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer

S. Kopetz; A. Grothey; E. Van Cutsem; R. Yaeger; H. Wasan; T. Yoshino; J. Desai; F. Ciardiello; A. Gollerkeri; K. Maharry; F. Loupakis; Y. Hong; N. Steeghs; T. Guren; H. Arkenau; P. García Alfonso; V. Sandor; J. Christy-Bittel; L. Anderson; J. Tabernero

doi:10.1093/annonc/mdz183.004

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer

S. Kopetz, A. Grothey, E. Van Cutsem, R. Yaeger, H. Wasan, T. Yoshino, J. Desai, F. Ciardiello, A. Gollerkeri, K. Maharry, F. Loupakis, Y. Hong, N. Steeghs, T. Guren, H. Arkenau, P. García Alfonso, V. Sandor, J. Christy-Bittel, L. Anderson, J. Tabernero

GI Medical Oncology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Original language	English (US)
Pages (from-to)	iv154
Journal	Annals of Oncology
Volume	30
DOIs	https://doi.org/10.1093/annonc/mdz183.004
State	Published - Jul 2019

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdz183.004

Cite this

Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Gollerkeri, A., Maharry, K., Loupakis, F., Hong, Y., Steeghs, N., Guren, T., Arkenau, H., García Alfonso, P., Sandor, V., Christy-Bittel, J., Anderson, L., & Tabernero, J. (2019). BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. Annals of Oncology, 30, iv154. https://doi.org/10.1093/annonc/mdz183.004

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer. / Kopetz, S.; Grothey, A.; Van Cutsem, E. et al.
In: Annals of Oncology, Vol. 30, 07.2019, p. iv154.

Research output: Contribution to journal › Article › peer-review

Kopetz, S, Grothey, A, Van Cutsem, E, Yaeger, R, Wasan, H, Yoshino, T, Desai, J, Ciardiello, F, Gollerkeri, A, Maharry, K, Loupakis, F, Hong, Y, Steeghs, N, Guren, T, Arkenau, H, García Alfonso, P, Sandor, V, Christy-Bittel, J, Anderson, L & Tabernero, J 2019, 'BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer', Annals of Oncology, vol. 30, pp. iv154. https://doi.org/10.1093/annonc/mdz183.004

@article{922eb04df90749fabd3e37cd5aa56e9d,

title = "BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer",

author = "S. Kopetz and A. Grothey and {Van Cutsem}, E. and R. Yaeger and H. Wasan and T. Yoshino and J. Desai and F. Ciardiello and A. Gollerkeri and K. Maharry and F. Loupakis and Y. Hong and N. Steeghs and T. Guren and H. Arkenau and {Garc{\'i}a Alfonso}, P. and V. Sandor and J. Christy-Bittel and L. Anderson and J. Tabernero",

year = "2019",

month = jul,

doi = "10.1093/annonc/mdz183.004",

language = "English (US)",

volume = "30",

pages = "iv154",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - BEACON CRC

T2 - a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer

AU - Kopetz, S.

AU - Grothey, A.

AU - Van Cutsem, E.

AU - Yaeger, R.

AU - Wasan, H.

AU - Yoshino, T.

AU - Desai, J.

AU - Ciardiello, F.

AU - Gollerkeri, A.

AU - Maharry, K.

AU - Loupakis, F.

AU - Hong, Y.

AU - Steeghs, N.

AU - Guren, T.

AU - Arkenau, H.

AU - García Alfonso, P.

AU - Sandor, V.

AU - Christy-Bittel, J.

AU - Anderson, L.

AU - Tabernero, J.

PY - 2019/7

Y1 - 2019/7

UR - http://www.scopus.com/inward/record.url?scp=85075246799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075246799&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz183.004

DO - 10.1093/annonc/mdz183.004

M3 - Article

C2 - 32085058

SN - 0923-7534

VL - 30

SP - iv154

JO - Annals of Oncology

JF - Annals of Oncology

ER -

BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E–mutant metastatic colorectal cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this